HomeComparePHRRF vs SBUX

PHRRF vs SBUX: Dividend Comparison 2026

PHRRF yields 4155.41% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHRRF wins by $10365691035278.81M in total portfolio value
10 years
PHRRF
PHRRF
● Live price
4155.41%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10365691035278.97M
Annual income
$9,897,164,253,693,497,000.00
Full PHRRF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — PHRRF vs SBUX

📍 PHRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHRRFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHRRF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHRRF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHRRF
Annual income on $10K today (after 15% tax)
$353,210.06/yr
After 10yr DRIP, annual income (after tax)
$8,412,589,615,639,472,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, PHRRF beats the other by $8,412,589,615,639,416,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHRRF + SBUX for your $10,000?

PHRRF: 50%SBUX: 50%
100% SBUX50/50100% PHRRF
Portfolio after 10yr
$5182845517639.57M
Annual income
$4,948,582,126,846,781,000.00/yr
Blended yield
95.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

PHRRF
No analyst data
Altman Z
-14.2
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHRRF buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHRRFSBUX
Forward yield4155.41%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$10365691035278.97M$157.5K
Annual income after 10y$9,897,164,253,693,497,000.00$65,840.13
Total dividends collected$10333779416010.36M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: PHRRF vs SBUX ($10,000, DRIP)

YearPHRRF PortfolioPHRRF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$426,241$415,541.24$11,107$407.21+$415.1KPHRRF
2$17,009,425$16,553,347.24$12,512$626.87+$17.00MPHRRF
3$635,556,863$617,356,778.09$14,366$978.69+$635.54MPHRRF
4$22,238,480,006$21,558,434,161.98$16,929$1,557.50+$22238.46MPHRRF
5$728,787,067,208$704,991,893,601.52$20,658$2,543.80+$728787.05MPHRRF
6$22,371,952,866,480$21,592,150,704,567.71$26,406$4,302.22+$22371952.84MPHRRF
7$643,400,978,312,961$619,462,988,745,827.60$35,877$7,622.00+$643400978.28MPHRRF
8$17,338,253,847,239,070$16,649,814,800,444,200.00$52,741$14,352.64+$17338253847.19MPHRRF
9$437,875,496,808,855,800$419,323,565,192,309,950.00$85,676$29,243.03+$437875496808.77MPHRRF
10$10,365,691,035,278,973,000$9,897,164,253,693,497,000.00$157,513$65,840.13+$10365691035278.81MPHRRF

PHRRF vs SBUX: Complete Analysis 2026

PHRRFStock

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

Full PHRRF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this PHRRF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHRRF vs SCHDPHRRF vs JEPIPHRRF vs OPHRRF vs KOPHRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.